Abstract
In a randomized, open study, the efficacy of fluconazole as a prophylaxis of recurrent oral candidiasis in patients with advanced stages of HIV-infection (CD4 cell count<100/mm3) was studied. For this purpose, the frequency of episodes of oral candidiasis during two different prophylaxis regimens (50 mg/day vs. 100 mg/day) were compared to an untreated control group. Sixty-five HIV-positive patients were included in the study from May, 1989 to January, 1990. Of these, 58 were evaluated over an observation time of 137–215 days. Prophylaxis with fluconazole clearly reduced the occurrence of oral candidiasis. In 20 out of 21 patients in the untreated control group, a total of 60 relapses occurred. In the prophylaxis group receiving 50 mg/day (group 2), two out of 18 patients had four relapses. In the group receiving 100 mg/day (group 3), four out of 19 patients had nine relapses in total. Of 3575 observation days in the control group, treatment due to oral candidiasis was necessary on 393 days (28 %). In group 2, on 57 of 3316 days (2 %), fluconazole in a higher dosage was administered for treatment. In group 3, relapse treatment with fluconazole 200 mg/day, or treatment with ketoconazole, became necessary in 116 out of 3314 observation days (3 %). In all relapses,Candida albicans cfu>103/ml were isolated in the oral wash-outs. As compared to the untreated control group, fluconazole prophylaxis in a daily dosage of 50 as well as 100 mg led to significantly less frequent relapses of oral candidiasis (p<0.01). The lower dosage of 50 mg/day, as compared to the higher dosage of 100 mg/day, resulted in no significant difference in the frequency of relapses (p=0.66). The fact that the patient gains more quality of life by longer symptom-free periods outweighs the disadvantages emerging from increased drug intake and higher costs.
Similar content being viewed by others
References
Daneshmend TK, Warnock DW Clinical pharmacokinetics of ketoconazole. Clinical Pharmacokinetics 1988, 14: 13–34.
Devenport MH, Crook D, Wynn V, Lees LJ Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives. British Journal of Clinical Pharmacology 1989, 27: 851–859.
Grant SM, Clissold SP Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in superficial and systemic mycosis. Drugs 1989, 37: 310–344.
Grant SM, Clissold SP Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial and systemic mycosis. Drugs 1990, 39: 877–916.
Meunier F, Aoun M, Gerard M Therapy for oropharyngeal candidiasis in the immunocompromised host: a randomized double-blind study of fluconazole vs. ketoconazole. Reviews of Infectious Diseases 1990, 12, Supplement 3: 364–368.
De Wit S, Weerts D, Goossens H, Clumeck N Comparison of fluconazole and ketoconazole for oropharyngeal candidiasis in AIDS. Lancet 1989, i: 746–747.
Dupont B, Drouhet E Fluconazole in the management of oropharyngeal candidiasis in a predominantly HIV antibody-positive group of patients. In: Fromtling RA (ed): Recent trends in the discovery, development and evaluation of antifungal agents. J.R. Prous Science Publishers, Madrid, 1987, p. 169–174.
Hay RJ Overview of studies of fluconazole in oropharyngeal candidiasis. Reviews of Infectious Diseases 1990, 12, Supplement 3: 334–337.
Just G, Gentschew G, Döhle M, Böttinger C, Helm EB, Stille W Fluconazole in the treatment of oropharyngeal candida infection in HIV-positive patients. Mycosis 1990, 33: 435–440.
Kibbler CC, Odds FC Fluconazole versus ketoconazole in oropharyngeal candidiasis in AIDS. Lancet 1989, i: 1130.
Smith DE, Gazzard BG Fluconazole versus ketoconazole in oropharyngeal candidiasis in AIDS. Lancet 1989, i: 1131.
Krüger HU, Schuler U, Zimmermann R, Ehninger G Absence of significant interaction of fluconazole with cyclosporin. Journal of Antimicrobial Chemotherapy 1989, 24: 781–786.
Lazar JD, Wilner KD Drug interactions with fluconazole. Reviews of Infectious Diseases 1990, 12, Supplement 3: 327–333.
Samonis G, Rolston K, Karl C, Miller P, Bodey GP Prophylaxis of oropharyngeal candidiasis with fluconazole. Reviews of Infectious Diseases 1990, 12, Supplement 3: 369–373.
Brodt HR, Helm EB, Werner A, Joetten A, Bergmann L, Klüver A, Stille W Verlaufsbeobachtungen bei Personen aus AIDS-Risikogruppen bzw. mit LAV/HTLV III Infektionen. Deutsche Medizinische Wochenschrift 1986, 111: 1175–1180.
Center of Disease Control: Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Morbidity and Mortality Weekly Report, 1987, 36, Supplement 15: 1–15.
Rozenberg M, Dekker AW, Branger J, Verhoef J A randomized study to compare fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukemia. Journal of Antimicrobial Chemotherapy 1991, 27: 369–376.
Tricot G, Joosten E, Boogaerts MA, Vandepitte J, Cauwenbergh G Ketoconazole vs. itraconzole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Reviews of Infectious Diseases 1987, 9, Supplement 1: 94–99.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Just-Nübling, G., Gentschew, G., Meißner, K. et al. Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients. Eur. J. Clin. Microbiol. Infect. Dis. 10, 917–921 (1991). https://doi.org/10.1007/BF02005444
Issue Date:
DOI: https://doi.org/10.1007/BF02005444